2,818
Views
0
CrossRef citations to date
0
Altmetric
Articles

Biochemical recurrence after radical prostatectomy – a large, comprehensive, population-based study with long follow-up

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 287-292 | Received 24 Feb 2022, Accepted 27 Jul 2022, Published online: 21 Aug 2022

References

  • Mottet N, Bellmunt J, Briers E, et al. EAU – ESTRO – ESUR – SIOG guidelines on prostate cancer. Online resource. EAU Guidelines Office, Arnhem, The Netherlands. https://uroweb.org/guidelines/prostate-cancer.2022.
  • Bianco FJ, Jr., Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (“trifecta”). Urology. 2005; 66(5 Suppl):83–94. 94.
  • Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169(2):517–523.
  • Van den Broeck T, van den Bergh RCN, Arfi N, et al. Prognostic value of biochemical recurrence Following treatment with curative intent for prostate cancer: a systematic review. Eur Urol. 2019;75(6):967–987.
  • Antonarakis ES, Feng Z, Trock BJ, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 2012;109(1):32–39.
  • Boorjian SA, Thompson RH, Tollefson MK, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011;59(6):893–899.
  • Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–439.
  • Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591–1597.
  • Andersen S, Richardsen E, Nordby Y, et al. Disease-specific outcomes of radical prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time. BMC Urol. 2014;14(1):49.
  • Bolton DM, Ta A, Bagnato M, et al. Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer. World J Urol. 2014;32(2):431–435.
  • Brooke HL, Talbäck M, Hörnblad J, et al. The swedish cause of death register. Eur J Epidemiol. 2017;32(9):765–773.
  • Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the swedish national inpatient register. BMC Public Health. 2011;11:450.
  • Tomic K, Berglund A, Robinson D, et al. Capture rate and representativity of The national prostate cancer register of Sweden. Acta Oncol. 2015;54(2):158–163.
  • Godtman R, Holmberg E, Stranne J, et al. High accuracy of swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm. Scand J Urol Nephrol. 2011;45(4):226–232.
  • Choudhury JB. Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Stat Med. 2002;21(8):1129–1144.
  • Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley; 1980.
  • R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2021. https://www.R-project.org/.
  • Cazzaniga W, Godtman RA, Carlsson S, et al. Population-based, nationwide registration of prostatectomies in Sweden. J Surg Oncol. 2019;120(4):803–812.
  • Statistics Sweden [Internet]. Life expectancy at birth and age 65 by sex 1970–2020 and projection 2021–2070. Available from: https://www.scb.se/en/finding-statistics/statistics-by-subject-area/population/population-projections/population-projections/pong/tables-and-graphs/life-expectancy-at-birth-and-age-65-by-sex-and-projection/.
  • Nguyen PL, Alibhai SMH, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825–836.
  • Wirth MP, Hakenberg OW, Froehner M. Antiandrogens in the treatment of prostate cancer. Eur Urol. 2007;51(2):306–314.
  • Nyberg M, Sjoberg DD, Carlsson SV, et al. Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the swedish LAPPRO trial. BJU Int. 2021;127: 361–368.